August 25, 2011 — Bayer HealthCare Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational compound, radium-223 chloride, exclusively licensed from Algeta ASA. The compound is for the treatment of castration-resistant (hormone-refractory) prostate cancer in patients with bone metastases.